DEA’s 3^rd Annual Supply Chain Conference

April 1–April 3, 2025

Orlando, FL

The Drug Enforcement Administration (DEA), Diversion Control Division, hosted a Supply Chain Conference April 1–April 3, 2025, at the Hilton Orlando, Orlando, Florida. This conference offered DEA registered Manufacturers, Distributors, Pharmacists, Importers or Exporters the opportunity to meet, share information and discuss concerns.

The conference provided a venue in which representatives from the supply chain industry, their affiliated associations, and DEA engaged in discussions concerning existing federal regulations, issues requiring regulatory changes, clarification of DEA policy, and the development of initiatives to reduce diversion of pharmaceutical controlled substances while ensuring an adequate and uninterrupted supply.

Tuesday, April 1, 2025 (DAY 1)
General Session

IT Transformation (Website, CONTACT center, Registrant Survey)
Matthew Strait, Deputy Assistant Administrator, DC Regulatory
Hyun Choe, Supervisor Information Technology Specialist

Registration Program Overview & Updates
Michelle McGregor, Acting Unit Chief, Registration and Program Support

CSOS 2.0 Update
Dunia Nooristani, Acting Unit Chief, CSOS

ARCOS Reporting
Samuel Weisman, Data Systems Analyst, Reports Analysis Unit

Substance and Chemical Controls and Related Issues
Dr. Terrence Boos, Section Chief, Drug and Chemical Evaluation Section

Wednesday, April 2, 2025 (DAY 2)
Quotas and Import/Export

International Drug Treaties and the CSA
Stacy Harper-Avilla, Section Chief, UN Reporting and Quota Section

Quotas – Aggregate Production & Individual Quotas
Kitty Chung, Drug Science Specialist, UN Reporting and Quota Section

Quotas – Online Applications Changes
Gregory Kavanagh, Drug Science Specialist, UN Reporting and Quota Section

Quotas – Research vs Manufacturing
Stacy Harper-Avilla, Section Chief, UN Reporting and Quota Section

Quotas – Year End Reporting
Greg Kavanaugh, Drug Science Specialist, UN Reporting and Quota Section

Imports and Exports of Controlled Substances and Listed Chemicals & Tableting & Encapsulating Machines
Jacob Prieto, Section Chief, Import/Export Section
Paul Repaci, Program Analyst, Import/Export Section

Regulatory Presentation
Ricardo Quintero, Section Chief, Regulatory Section

Thursday, April 3, 2025 (DAY 3)
Industry Trends

Insights & Innovations Shaping Tomorrow: Stimulants for ADHD: Friend or Foe?
Dr. Tim Wilens, Chief Division of Child and Adolescent Psychiatry, Massachusetts General Hospital

Drug Shortages
Matthew Strait, Deputy Assistant Administrator

Preparing for a DEA Inspection: What to expect during a DEA inspection?
Jennifer Reed, Staff Coordinator, Liaison Section

DEA Reporting Requirements & Reporting Tools & Drug Trends
Ryan Dorsey, Acting Deputy Assistant Administrator, DC Operations

IQVIA: Stimulant, Ketamine, and Buprenorphine Trends in the United States
Rosenie Thelus, IQVIA Government Solutions

NABP Pulse
Josh Bolin, Associate Executive Director, Government Affairs and Innovation, National Association of Boards of Pharmacy (NABP)